Trevi Therapeutics, Inc.
TRVI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $39 | $24 | $20 | $23 |
| G&A Expenses | $12 | $10 | $10 | $9 |
| SG&A Expenses | $12 | $10 | $10 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $52 | $34 | $30 | $32 |
| Operating Income | -$52 | -$34 | -$30 | -$32 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $5 | $1 | -$1 |
| Pre-Tax Income | -$48 | -$29 | -$29 | -$34 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$48 | -$29 | -$29 | -$34 |
| % Margin | – | – | – | – |
| EPS | -0.47 | -0.29 | -0.45 | -1.49 |
| % Growth | -62.1% | 35.6% | 69.8% | – |
| EPS Diluted | -0.47 | -0.29 | -0.45 | -1.49 |
| Weighted Avg Shares Out | 101 | 99 | 65 | 23 |
| Weighted Avg Shares Out Dil | 101 | 99 | 65 | 23 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $5 | $2 | $0 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$48 | -$29 | -$28 | -$33 |
| % Margin | – | – | – | – |